Irene Becklund, the Principal Accounting Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of transactions involving the company's Class A Common Stock. According to the SEC Form 4 filing, Becklund sold shares totaling $336,348. The sales occurred on December 16 and 17, with prices ranging from $29.58 to $32.20 per share.
In addition to the sales, Becklund also exercised stock options on December 16, acquiring 472 shares at a price of $9.41 per share. The transactions were carried out under a Rule 10b5-1 trading plan, which was adopted on September 11, 2023.
Following these transactions, Becklund's direct ownership of Hims & Hers Health stock stands at 7,319 shares.
In other recent news, Hims & Hers Health demonstrated impressive financial growth, with Q3 sales increasing by 77% year-over-year, surpassing $400 million, and an adjusted EBITDA over $50 million. The company also forecasted Q4 2024 revenue between $465 million and $470 million, marking an 89% to 91% year-over-year increase, and full-year revenue expected to be between $1.46 billion and $1.465 billion. Morgan Stanley (NYSE:MS) assigned an Overweight rating on Hims & Hers stock, citing its impressive revenue growth rate and potential.
Hims & Hers Health also announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound. This collaboration involves integrating with LillyDirect, a self-pay pharmacy channel, further enhancing the company's healthcare services.
On the analyst front, TD Cowen reaffirmed its Buy rating on Hims & Hers Health, while BofA Securities downgraded it from Buy to Underperform. Piper Sandler and Needham, however, raised their price targets, maintaining Neutral and Buy ratings respectively.
The company also expanded its board of directors, appointing Deb Autor as a new independent director. These recent developments provide a snapshot of the evolving landscape for Hims & Hers Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.